促红细胞生成素联用氯沙坦治疗慢性心力衰竭  

Treatment with erythropoietin and losartan in patients with chronic heart failure

作　　者：于建华[1] 解朝永[1] 赵晖[1] 

机构地区：[1]山东省枣庄市立医院内一科,277102

出　　处：《中国实用医药》2007年第25期11-13,共3页China Practical Medicine

摘　　要：目的评价在慢性充血性心衰标准治疗的基础上加用促红细胞生成素和氯沙坦的临床疗效。方法入选的106例患者随机分为治疗组和对照组。治疗组(促红细胞生成素联用氯沙坦组)53例,对照组(常规治疗组)53例,进行对照分析。结果①治疗组治疗前后贫血指标及心功能指标的改善均优于对照组(P<0.05);②治疗组治疗前后生活质量评分及运动耐量的改善均优于对照组(P<0.05);③治疗组治疗后再住院率显著低于对照组(P<0.01);④两组治疗后未见明显不良反应。结论促红细胞生成素联用氯沙坦治疗慢性心力衰竭安全有效,心功能指标、贫血指标及运动耐力提高,减少了总住院时间,改善了生活质量。Objective To assess the effects of erythropoietin (EPO) and losartan in patients with chronic heart failure (CHF). Methods 106 patients with CHF (NYHA class Ⅱ-Ⅳ) were randomly divided into 2 groups.53 in treatment grouop were treated by standard CHF medications plus EPO and losartan,53 in control group received standard CHF medications.Results There were significant increase in cardic function,Hb levels,exercise capacity,quality of life and 6 minutes walk distance in EPO group (P<0.05),but they were no significant changes in control group(P>0.05),and the rates of rehospitalization were obvious reduced in treatment group(P<0.01).Conclusion Treatment with EPO and losartan might improve the cardic function,exercise capacity,life quality and reduce the rates of rehospitalization of the patients with cardiac failure.

关 键 词：慢性心力衰竭 贫血 促红细胞生成素 氯沙坦 运动耐量 

分 类 号：R541.6[医药卫生—心血管疾病]